The emerging role of VEGF in diabetic kidney disease

Nephrology Dialysis Transplantation

Volumn 18, Issue 8, 2003, Pages 1427-1430

  Khamaisi, Mogher ^a,b   Schrijvers, Bieke F ^c   De Vriese, An S ^c   Raz, Itamar ^b   Flyvbjerg, Allan ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Advanced glycation endproduct; Angiotensin converting enzyme; Antibody; Experimental diabetes; Type 1 and type 2 diabetes

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; ADVANCED GLYCATION END PRODUCT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GROWTH HORMONE; LISINOPRIL; NITRIC OXIDE SYNTHASE; PLACEBO; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; ANIMAL MODEL; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; EDITORIAL; GLOMERULUS FILTRATION; HUMAN; HYPERGLYCEMIA; KIDNEY CLEARANCE; MICROALBUMINURIA; MORBIDITY; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEINURIA; RISK FACTOR; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES;

ANIMALS; DIABETIC NEPHROPATHIES; ENDOTHELIUM, VASCULAR; HUMANS; KIDNEY GLOMERULUS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0042665642     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg242     Document Type: Editorial

References (32)

1. Tilton RG, Kawamura T, Chang KC et al. Vascular dysfunction induced by elevated glucose in rats is mediated by vascular endothelial growth factor. J Clin Invest 1997; 99: 2192-2202
2. Flyvbjerg A. Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia 2000; 43: 1205-1223
3. De Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001; 12: 993-1000
4. De Vriese AS, Tilton RG, Stephan CC, Lameire N. Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane. J Am Soc Nephrol 2001; 12: 1734-1741
5. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9-22
6. Ferrara N, Houck KA, Jakeman LB, Winer J, Leung DW. The vascular endothelial growth factor family of polypeptides. J Cell Biochem 1991; 47: 211-218
7. Senger DR, Connolly DT, Van de Water L, Feder J, Dvorak HF. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 1990; 50: 1774-1778
8. 125I]-VEGF binding sites. J Am Soc Nephrol 1998; 9: 1032-1044
9. Pupilli C, Lasagni L, Romagnani P et al. Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells. J Am Soc Nephrol 1999; 10: 245-255
10. Williams B, Gallacher B, Patel H, Orme C. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes 1997; 46: 1497-1503
11. Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein and NO production in human endothelial cells. Am J Physiol 1998; 274: H1054-H1058
12. Cooper ME, Vranes D, Youssef S et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999; 48: 2229-2239
13. Tsuchida K, Makita Z, Yamagishi S et al. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia 1999; 42: 579-588
14. Hoshi S, Shu Y, Yoshida F et al. Podocyte injury promotes progressive nephropathy in zucker diabetic fatty rats. Lab Invest 2002; 82: 25-35
15. Malamitsi-Puchner A, Sarandakou A, Tziotis J, Dafogianni C, Bartsocas CS. Serum levels of basic fibroblast growth factor and vascular endothelial growth factor in children and adolescents with type 1 diabetes mellitus. Pediatr Res 1998; 44: 873-875
16. Chiarelli F, Spagnoli A, Basciani F et al. Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with Type 1 diabetes mellitus: relation to glycaemic control and microvascular complications. Diabet Med 2000; 17: 650-656
17. McLaren M, Elhadd TA, Greene SA, Belch JJ. Elevated plasma vascular endothelial cell growth factor and thrombomodulin in juvenile diabetic patients. Clin Appl Thromb Hemost 1999; 5: 21-24
18. Hovind P, Tarnow L, Østergaard PB, Parving H-H. Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. Kidney Int 75: S56-S61
19. Chaturvedi N, Fuller JH, Pokras F, Rottiers R, Papazoglou N, Aiello LP. Circulating plasma vascular endothelial growth factor and microvascular complications of type 1 diabetes mellitus: the influence of ACE inhibition. Diabet Med 2001; 18: 288-294
20. Wasada T, Kawahara R, Katsumori K, Naruse M, Omori Y. Plasma concentration of immunoreactive vascular endothelial growth factor and its relation to smoking. Metabolism 1998; 47: 27-30
21. Cha DR, Kim NH, Yoon JW et al. Role of vascular endothelial growth factor in diabetic nephropathy. Kidney Int 2000; 77: S104-S112
22. Flyvbjerg A, Schrijvers BF, De Vriese AS, Tilton RG, Rasch R. Compensatory glomerular growth following unilateral nephrectomy is VEGF dependent. Am J Physiol Endocrinol Metab 2002; 283: E362-E366
23. Schrijvers BF, Rasch R, Tilton RG, Flyvbjerg A. High protein-induced glomerular hypertrophy is vascular endothelial growth factor-dependent. Kidney Int 2002; 61: 1600-1604
24. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG, Rasch R. Amelioration of long-term renal changes by administration of a neutralizing VEGF-ab in obese type 2 diabetic mice. Diabetes 2002; 51: 3090-3094
25. Gilbert RE, Kelly DJ, Cox AJ et al. Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia 2000; 43: 1360-1367
26. Hogeboom van Buggenum IM, Polak BC et al. Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy. Diabetologia 2002; 45: 203-209
27. Chaturvedi N, Fuller JH, Pokras F, Rottiers R, Papazoglou N, Aiello LP; EUCLID Study Group. Circulating plasma vascular endothelial growth factor and microvascular complications of type 1 diabetes mellitus: the influence of ACE inhibition. Diabet Med 2001; 18: 288-294
28. Ozaki H, Seo MS, Ozaki K et al. Blockade of vascular endothelial cell growth factor receptor signalling is sufficient to completely prevent retinal neovascularization. Am J Pathol 2000; 156: 697-707
29. Benjamin LE. Glucose, VEGF-A and diabetic complications. Am J Pathol 2001; 158: 1181-1184
30. Pal S, Claffey KP, Dvorak HF, Mukhopadhyay D. The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways. J Biol Chem 1997; 272: 27509-27512
31. Ostendorf T, Kunter U, Eitner F et al. VEGF(165) mediates glomerular endothelial repair. J Clin Invest 1999; 104: 913-923
32. Lai YK, Shen WY, Brankov M, Lai CM, Constable IJ, Rakoczy PE. Potential long-term inhibition of ocular neovascularization by recombinant adeno-associated virus-mediated secretion gene therapy. Gene Ther 2002; 12: 804-813